The target audience for this activity is pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with hematologic malignancies that are eligible for CAR T-cell therapy as well other stakeholders in hematology/oncology practice.
The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with hematologic malignancies that are eligible for CAR T-cell therapy using a case-based approach with a strong focus on the thought processes needed to solve patient care problems.
Upon completion of this activity, participants should be able to:
Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE, LLC policy. ProCE, LLC is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity.
Craig Freyer, PharmD, BCOP
Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Craig W. Freyer, PharmD, BCOP, has disclosed that he has received consulting fees from Astellas, EUSA, and Servier.
Andrew Lin, PharmD, BCOP
Clinical Pharmacy Specialist
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York
Andrew Lin, PharmD, BCOP, has disclosed that he has received consulting fees from EUSA, Incyte, and Medexus.
The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 28, 2022, through April 27, 2023:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-090-H01-P has been assigned to this home study application-based activity (initial release date 4-1-22). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.